A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

Subcutaneous pegylated interferon beta-1a (peginterferon beta-1a [PEG-IFN]) 125 μg every two or four weeks has been studied in relapsing-remitting multiple sclerosis (RRMS) patients in the pivotal Phase 3 ADVANCE trial. In the absence of direct comparative evidence, a network meta-analysis (NMA) was...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolley, Keith, Hutchinson, Michael, You, Xiaojun, Wang, Ping, Sperling, Bjoern, Taneja, Ankush, Siddiqui, Mohammed Kashif, Kinter, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454514/
https://www.ncbi.nlm.nih.gov/pubmed/26039748
http://dx.doi.org/10.1371/journal.pone.0127960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454514/
https://www.ncbi.nlm.nih.gov/pubmed/26039748
http://dx.doi.org/10.1371/journal.pone.0127960

Ejemplares similares